This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Wolff, A. C. Search for Related Content PubMed PubMed Citation Articles by Wolff, A. C.

Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, The Johns Hopkins University, Baltimore, Maryland, USA

Correspondence: Antonio C. Wolff, M.D., The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Bunting-Blaustein Cancer Research Building, 1650 Orleans Street, Room 189, Baltimore, Maryland 21231-1000, USA. Telephone: 410-614-4192; Fax: 410-955-0125; e-mail: awolff{at}jhmi.edu

Breast cancer research is entering a new and promising phase, with greater focus on patient quality of life and therapy selection based on specific targets of interest. Growth factor pathway modulators represent an area of increasing interest for clinicians treating various cancer types, including breast cancer. Therapeutic strategies combining cytotoxic drugs with specific targets using small molecules and targeted antibody therapy may help circumvent potential growth factor survival mechanisms in solid tumors. One of the challenges when combining these agents, however, is the potential for pharmacodynamic and pharmacokinetic interactions, making safety an important consideration. An example of a growth factor pathway modulator with clinical application in breast cancer is trastuzumab. Based on its efficacy in metastatic disease, ongoing clinical trials are examining trastuzumab in combination with chemotherapy in the adjuvant setting. Concerns about the cardiac safety of trastuzumab given concomitantly with conventional anthracyclines support ongoing investigations of regimens combining it with liposomal anthracyclines, based on available data indicating a more favorable cardiac safety profile with liposomal formulations.

Key Words. Anthracyclines • Liposome • Adjuvant chemotherapy • Breast neoplasms • Monoclonal antibodies

This article has been cited by other articles:

				J. O'Shaughnessy Liposomal Anthracyclines for Breast Cancer: Overview Oncologist, August 1, 2003; 8(90002): 1 - 2. [Full Text] [PDF]

				E. Rivera Liposomal Anthracyclines in Metastatic Breast Cancer: Clinical Update Oncologist, August 1, 2003; 8(90002): 3 - 9. [Abstract] [Full Text] [PDF]